Eric Venker - 20 May 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: President & Immunovant CEO
Issuer ticker: ROIV
Reported as of: 20 May 2026
Net transaction value: -$6,054,000
SEC form: 4
Accepted by SEC: 22 May 2026, 18:25:47 UTC
Prior SEC filing: 22 Apr 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker

Key filing fact

Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 22 May 2026.

Key facts

This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 18:25.

Change

Previous filing in this sequence was filed on 22 Apr 2026.
Current net transaction value: -$6,054,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801917 Primary reporting owner

Venker Eric

Relationship: President & Immunovant CEO
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Tax liability

Transaction value
Shares: -34,483
Change %: -2.1%
Price: $32.41^*
Shares after: 1,613,063
Date: 20 May 2026
Ownership: Direct
Footnotes: F1

ROIV transaction

Common Shares

Options Exercise

Transaction value
Shares: +200,000
Change %: +12%
Price: $3.85^*
Shares after: 1,813,063
Date: 22 May 2026
Ownership: Direct

ROIV transaction

Common Shares

Sale

Transaction value: $6,054,000
Shares: -200,000
Change %: -11%
Price: $30.27
Shares after: 1,613,063
Date: 22 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -200,000
Change %: -4.3%
Price: $0.000000^*
Shares after: 4,444,834
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $3.85
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Footnote F3

Reflects an award of stock options to purchase Common Shares that is fully vested.